"Ulcerative colitis is a complex immune disease, and more than half of UC patients have not experienced remission with currently available conventional or biologic treatment options," said lead investigator MD. "The significant rates of remission observed through the 8-week induction, coupled with a safety profile that is well-documented through years of research and use in other immune diseases, demonstrate the potential for ustekinumab as an effective treatment for UC." A single intravenous (IV) dose of ustekinumab induced clinical remission and response in adults with moderate to severe ulcerative colitis (UC) who previously had an inadequate response or were intolerant to conventional or biologic therapies, according to new data from the Phase 3 trial.
Study authors at the American College of Gastroenterology (ACG) Scientific Meeting 2018 presented late-breaking data from the…
